Shots: MoonLake Immunotherapeutics reported positive 52 Wks. (n=396) results from the P-III (VELA-1) and (VELA-2) studies, demonstrating durable efficacy of sonelokimab in adults with moderate-to-severe HS At Week 52, 67.2% of pts. achieved HiSCR75, 33.1% achieved HiSCR100, and 26.0% reached inflammatory remission (IHS4-100). Sonelokimab also showed substantial improvements in quality of life and pain reduction,…